Top Stories

Memorial Hermann to Expand Home Infusion Therapy with KabaFusion

Image alt text

The initiative allows patients to receive intravenous medication at home instead of traveling to the hospital.

Memorial Hermann Health System has entered into a services agreement with KabaFusion to provide home infusion therapy for patients with chronic conditions and those requiring intravenous immunoglobulin (IVIG) treatment.

The initiative allows patients to receive intravenous medication at home instead of traveling to the hospital.

Broader Care Access

Memorial Hermann currently offers short-term home infusion therapy. With KabaFusion’s support, Memorial Hermann Home Infusion Pharmacy will extend services to patients needing treatments over a longer period.

“We are always looking for new ways to advance the patient experience and improve health care for our patients,” said Binita Patel, PharmD, MS, CPEL, vice president of pharmacy services for Memorial Hermann. “This is the first time we have worked with a home infusion platform, and we believe working with KabaFusion will allow patients to receive personalized, compassionate care without leaving the comfort of their homes.”

Partnership with KabaFusion

KabaFusion, founded in 2010, provides specialty infusion pharmacy services and home nursing support for therapies prescribed in neurology, immunology, oncology, pain management, infectious disease, cardiology, dermatology, and nutrition.

“We are excited to partner with Memorial Hermann to provide high-quality, in-home care to the patients that need it most,” said Dr. Sohail Masood, founder and CEO of KabaFusion. “Every step KabaFusion takes in providing patient-focused care to new markets and greater segments of the population is a step towards an increased number of positive clinical and patient outcomes.”

More Articles By This Author


Show All
Newsletter

Signup for newsletter and stay updated

When digital health information is abundant but time is limited, access to curated, high-quality insights is more crucial than ever. Subscribe to our daily newsletter

Sign In

Sign In / Sign Up

Sign In & Stay updated with the latest news and analysis

+91